Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
16 06 2020
Historique:
received: 14 01 2020
accepted: 31 03 2020
pubmed: 17 4 2020
medline: 18 12 2020
entrez: 17 4 2020
Statut: epublish

Résumé

HIV-1 envelope (Env) trimers, stabilized in a prefusion-closed conformation, can elicit humoral responses capable of neutralizing HIV-1 strains closely matched in sequence to the immunizing strain. One strategy to increase elicited neutralization breadth involves vaccine priming of immune responses against a target site of vulnerability, followed by vaccine boosting of these responses with prefusion-closed Env trimers. This strategy has succeeded at the fusion peptide (FP) site of vulnerability in eliciting cross-clade neutralizing responses in standard vaccine-test animals. However, the breadth and potency of the elicited responses have been less than optimal. Here, we identify three mutations (3mut), Met302, Leu320, and Pro329, that stabilize the apex of the Env trimer in a prefusion-closed conformation and show antigenically, structurally, and immunogenically that combining 3mut with other approaches (e.g., repair and stabilize and glycine-helix breaking) yields well-behaved clade C-Env trimers capable of boosting the breadth of FP-directed responses. Crystal structures of these trimers confirmed prefusion-closed apexes stabilized by hydrophobic patches contributed by Met302 and Leu320, with Pro329 assuming canonically restricted dihedral angles. We substituted the N-terminal eight residues of FP (FP8, residues 512 to 519) of these trimers with the second most prevalent FP8 sequence (FP8v2, AVGLGAVF) and observed a 3mut-stabilized consensus clade C-Env trimer with FP8v2 to boost the breadth elicited in guinea pigs of FP-directed responses induced by immunogens containing the most prevalent FP8 sequence (FP8v1, AVGIGAVF). Overall, 3mut can stabilize the Env trimer apex, and the resultant apex-stabilized Env trimers can be used to expand the neutralization breadth elicited against the FP site of vulnerability.

Identifiants

pubmed: 32295908
pii: JVI.00074-20
doi: 10.1128/JVI.00074-20
pmc: PMC7307166
pii:
doi:

Substances chimiques

AIDS Vaccines 0
Antibodies, Neutralizing 0
HIV Antibodies 0
Peptides 0
Vaccines, Subunit 0
env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
J Virol. 2002 Sep;76(17):8875-89
pubmed: 12163607
Nature. 2011 Nov 23;480(7377):336-43
pubmed: 22113616
PLoS Pathog. 2013 Sep;9(9):e1003618
pubmed: 24068931
Nature. 2019 Apr;568(7752):415-419
pubmed: 30971821
Nat Commun. 2017 Nov 21;8(1):1655
pubmed: 29162799
PLoS Pathog. 2018 May 10;14(5):e1006986
pubmed: 29746590
Science. 2003 Jun 27;300(5628):2065-71
pubmed: 12829775
Nat Commun. 2016 Jun 28;7:12040
pubmed: 27349805
Nature. 2014 Nov 6;515(7525):138-42
pubmed: 25186731
Nat Commun. 2017 Nov 16;8(1):1528
pubmed: 29142300
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):303-12
pubmed: 21460448
ACS Chem Biol. 2011 Oct 21;6(10):1069-77
pubmed: 21793507
Cell Host Microbe. 2018 Jun 13;23(6):832-844.e6
pubmed: 29902444
PLoS One. 2011;6(12):e27780
pubmed: 22164215
Immunity. 2014 May 15;40(5):657-68
pubmed: 24768347
Cell Rep. 2017 Dec 5;21(10):2992-3002
pubmed: 29212041
Nature. 2009 Apr 2;458(7238):636-40
pubmed: 19287373
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
Biochemistry. 2013 Sep 10;52(36):6249-57
pubmed: 23944979
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Virol. 2015 May;89(10):5318-29
pubmed: 25740988
Nature. 2014 Oct 23;514(7523):455-61
pubmed: 25296255
Cell. 2015 Jun 4;161(6):1280-92
pubmed: 26004070
Immunity. 2017 May 16;46(5):792-803.e3
pubmed: 28514686
Cell Rep. 2018 Apr 10;23(2):584-595
pubmed: 29642014
Cell Rep. 2017 Aug 22;20(8):1805-1817
pubmed: 28834745
Nature. 2017 Jul 20;547(7663):360-363
pubmed: 28700571
Nat Struct Mol Biol. 2010 Aug;17(8):955-61
pubmed: 20622876
Nat Struct Mol Biol. 2017 Apr;24(4):370-378
pubmed: 28218750
Nature. 1998 Jun 18;393(6686):648-59
pubmed: 9641677
Nature. 2007 Feb 15;445(7129):732-7
pubmed: 17301785
J Virol. 2015 Oct 14;90(1):76-91
pubmed: 26468542
PLoS One. 2019 Apr 17;14(4):e0215163
pubmed: 30995238
J Virol. 1993 Jul;67(7):3978-88
pubmed: 7685405
Science. 2016 May 13;352(6287):828-33
pubmed: 27174988
Nature. 2008 Sep 4;455(7209):109-13
pubmed: 18668044
Nat Struct Mol Biol. 2015 Jul;22(7):522-31
pubmed: 26098315
Cell. 2018 Mar 8;172(6):1319-1334
pubmed: 29522750
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
J Virol. 2006 Jun;80(12):6093-105
pubmed: 16731948
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
J Virol. 2015 Dec 30;90(6):2806-17
pubmed: 26719252
J Virol. 2006 Jul;80(14):6865-72
pubmed: 16809292
Nat Commun. 2015 Sep 03;6:8143
pubmed: 26333350
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
Nat Commun. 2019 May 29;10(1):2355
pubmed: 31142746
Immunity. 2019 Jan 15;50(1):241-252.e6
pubmed: 30552025
J Virol. 2017 Apr 28;91(10):
pubmed: 28275193
J Virol. 2015 Dec 30;90(6):2740-55
pubmed: 26719262
Nat Commun. 2019 Jan 3;10(1):47
pubmed: 30604750
Virus Res. 2011 Dec;162(1-2):19-30
pubmed: 21963677
Immunity. 2017 Apr 18;46(4):690-702
pubmed: 28423342
Virology. 2015 May;479-480:498-507
pubmed: 25866377
Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6325-9
pubmed: 8327513
Cell. 2015 Dec 17;163(7):1702-15
pubmed: 26687358
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Science. 2014 Nov 7;346(6210):759-63
pubmed: 25298114
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
Nat Med. 2018 Jun;24(6):857-867
pubmed: 29867235
Nat Struct Mol Biol. 2016 Jan;23(1):81-90
pubmed: 26689967
Cell. 2019 Jul 25;178(3):567-584.e19
pubmed: 31348886
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
Cell Rep. 2020 Apr 7;31(1):107488
pubmed: 32268107
Vet Res. 2007 Mar-Apr;38(2):281-97
pubmed: 17296157
J Biol Chem. 2019 Apr 5;294(14):5616-5631
pubmed: 30728245
Science. 2009 Nov 20;326(5956):1123-7
pubmed: 19965434
Cell Rep. 2015 Apr 28;11(4):539-50
pubmed: 25892233
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701

Auteurs

Gwo-Yu Chuang (GY)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Yen-Ting Lai (YT)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Jeffrey C Boyington (JC)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Cheng Cheng (C)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Hui Geng (H)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Sandeep Narpala (S)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Reda Rawi (R)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Stephen D Schmidt (SD)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Yaroslav Tsybovsky (Y)

Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Raffaello Verardi (R)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Kai Xu (K)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Yongping Yang (Y)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Baoshan Zhang (B)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Michael Chambers (M)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Anita Changela (A)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Angela R Corrigan (AR)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Rui Kong (R)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Adam S Olia (AS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Li Ou (L)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Edward K Sarfo (EK)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Shuishu Wang (S)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Winston Wu (W)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Nicole A Doria-Rose (NA)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Adrian B McDermott (AB)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

John R Mascola (JR)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jmascola@nih.gov pdkwong@nih.gov.

Peter D Kwong (PD)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jmascola@nih.gov pdkwong@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH